Latest Content

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

PRV211 was safe with no SAEs, systemic toxicities, or DLTs for the treatment of patients with invasive oral cavity cancer.

Mayo Clinic Comprehensive Cancer Center is expanding surgical options for patients undergoing treatment or risk-reducing procedures for breast cancer.

Real-world, head-to-head data show an improvement in OS with apalutamide plus ADT vs darolutamide plus ADT without docetaxel in mCSPC.

An NDA for zanzalintinib plus atezolizumab in pretreated metastatic colorectal cancer is under review by the FDA.

Marc J. Braunstein, MD, PhD, details the significance of the FDA approval of daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.

Dana M. Chase, MD, Robert Neff, MD, and Maurie Markman, MD, comment on the current state of HPV vaccination and screening during cervical cancer awareness month.

EMA CHMP backs niraparib plus abiraterone with ADT for BRCA1/2-mutant mHSPC, supported by data from the AMPLITUDE study.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

Monitoring thymidine kinase activity levels may provide insights on response to CDK4/6 inhibitor therapy in breast cancer.